Investors
Contact
en
Global United States
Overview iTrack™ iTrack™ Advance Molteno3®
AlphaRET
Overview
Overview ASX Announcements Presentations Share Registry Board of Directors Corporate Governance

Advancing
clinical
outcomes and
improving
patient quality
of life

WE ARE NOVA EYE MEDICAL

With a legacy that spans more than 30 years in ophthalmology, Nova Eye Medical designs, develops, manufactures and markets a portfolio of proprietary glaucoma treatment technologies. Underpinning each of these technologies is our commitment to advance clinical outcomes and improve patient quality of life.

Latest News

See all

INVESTOR WEBINAR PRESENTATION - SHARECAFE

ASX Announcement General iTrack Molteno3 AlphaRET

15 Sept, 2023

Evans & Partners Small Cap Healthcare Conference Presentation

ASX Announcement General iTrack Molteno3 AlphaRET

12 Sept, 2023

iTrack™ Advance Real-World Registry Data and CATALYST Study Data to be Presented at the 2023 ESCRS Annual Congress, Vienna

Media Release General iTrack Molteno3 AlphaRET

1 Sept, 2023

Latest Events

See all

Interventional Glaucoma Congress (IGC) 2023

Salt Lake City

5 - 8 Oct, 2023

Register for updates

The Royal Australian and New Zealand College of Ophthalmologists (RANZCO) 2023

Perth, Australia

20 - 24 Oct, 2023

Register for updates

American Academy of Ophthalmology (AAO) 2023

San Francisco, California

3 - 6 Nov, 2023

Register for updates

World Glaucoma Congress

Rome, Italy

June 28 – July 1

Learn more
Based on the principles of angioplasty, iTrack™ is an implant-free glaucoma surgery that combines 360-degree catheterization with viscodilation to mechanically remove blockages and to dilate Schlemm’s canal in order to remove outflow resistance — achieving excellent clinical outcomes while also preserving the viability of subsequent glaucoma treatments.

Visit the iTrack™ website
Glaucoma-iTrack.com

Visit the iTrack™ Advance website
iTrack-Advance.com

The Molteno3® Glaucoma Drainage Device is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe and complex glaucoma, with the added benefit of a simplified surgical procedure.

Visit the Molteno3 website
Glaucoma-Molteno.com

AlphaRET is a wholly owned subsidiary of Nova Eye Medical Limited, established to drive the commercial development of the 2RT™ project. 2RT™ is a breakthrough nano-pulse laser technology that stimulates the eye’s natural healing response to treat intermediate age-related macular degeneration (AMD), one of the world’s leading causes of blindness.
Visit Alpha-RET.com
This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More